www.foxbusiness.com

www.foxbusiness.com
Share

www.foxbusiness.com

 •  October 1

Americans spent $457 billion on prescription drugs in 2015, according to a recent issue of the AARP Bulletin. The most popular brand-name drugs rose 208 percent between 2008 and 2016—bad news for retirees living on a fixed income, and according to one senior citizens lobbying group, because Medicare doesn’t have the authority to negotiate drug...

www.foxbusiness.com

 •  September 7

New Mexico sued several major pharmaceutical companies and wholesale drug distributors on Thursday, arguing the corporations are partly to blame for rampant opioid addiction rates in the state. The lawsuit, filed in state court in Santa Fe County, follows the lead of half a dozen other states that have also sued over the opioid crisis. All claim...

www.foxbusiness.com

 •  September 7

INDIANAPOLIS – Eli Lilly will slash its global workforce by nearly 9 percent as the drugmaker closes some research sites and pushes to trim fixed costs. The Indianapolis company said Thursday it will cut about 3,500 positions, mostly through a voluntary retirement program in the United States. The insulin and cancer treatment maker employed 41,240...

www.foxbusiness.com

 •  August 14

Roche Holding AG shares jumped 6.5% on a single day in early March when the drugmaker said its new breast-cancer treatment, Perjeta, helped prolong average patient survival in a clinical study. But the stock gave up nearly all those gains three months later, when the Swiss company disclosed full details of the trial at a medical conference. The...

www.foxbusiness.com

 •  August 11

A branded HIV drug that's been shown to reduce the risk of infection with the virus by 86% is proving too expensive for some at-risk European patients. England's National Health Service thinks it has a solution. The high price of Gilead Sciences Inc.'s HIV drug Truvada has deterred many countries from providing the pill as a preventive treatment...

www.foxbusiness.com

 •  August 9

NEW YORK – Mylan's second-quarter profit and revenue surged, but not as much as Wall Street had expected and the company is taking a more conservative view going forward because of "ongoing challenges and the uncertain U.S. regulatory environment." Shares tumbled 5 percent and were trading close to four-year lows at the opening bell Wednesday. The...

www.foxbusiness.com

 •  August 3

This photo provided by AbbVie shows the drug Mavyret. On Thursday, Aug. 3, 2017, the Food and Drug Administration approved Mavyret to treat all forms of hepatitis C. The drug works in as little as eight weeks and is for patients without significant ... U.S. regulators have approved the first drug to treat all forms of hepatitis C in as little as...

www.foxbusiness.com

 •  August 1

LONDON – The U.S. Food and Drug Administration has agreed to speed up the process required for development and regulatory review of AstraZeneca PLC's (AZN.LN) blood cancer drug acalabrutinib. Pharmaceutical firm AstraZeneca and its hematology research and development centre Acerta Pharma, said today that the FDA has granted Breakthrough Therapy...

www.foxbusiness.com

 •  May 9

French drugmaker Sanofi has pledged to peg U.S. drug price rises to below healthcare inflation in a move that limits increases for any product this year to 5.4 percent, unless there are exceptional circumstances. The price promise goes one step beyond action taken by a number of other large pharmaceutical companies that have undertaken to keep...

www.foxbusiness.com

 •  May 1

Pfizer Inc. executives hope the late-stage clinical trials on its new sickle-cell-anemia treatment will show strong benefits for sufferers of the blood disease. But if they don't, there will be a small silver lining: Pfizer didn't pay for the trials. Last year, NovaQuest Capital Management LLC, a private-equity firm focused on life sciences, agreed...